South Korea Antihistamine Market Insight
Published: 01 June 2026 | Report Format: Electronic (PDF)
South Korea market for antihistamines is forecast to grow at a CAGR of 5.7%, driven by the rise in cases of allergic rhinitis, respiratory ailments, and growing demand for OTC allergy drugs.
South Korea Antihistamine Market Insights Forecasts to 2035
- The South Korea Antihistamine Market Size Was Estimated USD 1.12 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.7% from 2025 to 2035
- The South Korea Antihistamine Market Size is Expected to rise around USD 1.95 Billion by 2035
Notable Insights for the South Korea Antihistamine Market
- The Second Generation Antihistamines category held about 61% share of the South Korea Antihistamine Market share in 2025 because of the increased preference for non-sedating allergy medication and products providing long-lasting relief from symptoms.
- The Allergic Rhinitis category had almost 46% share of the market in 2025 because of the increasing seasonal allergies, high urban pollution levels, and increasing knowledge regarding the management of respiratory allergy problems in South Korea.
- Pfizer Inc.'s revenue for 2025 exceeded over USD 63 billion based on the growing demand for its pharmaceutical products such as allergy therapies, respiratory medications, and specialized health care products.
Download the eBook (ToC)
- Increasing investment in AI-based research and development systems for pharmaceuticals, digital healthcare systems, and advanced allergy therapies is promoting market growth, and advanced antihistamine formulations can provide effective symptom management efficiency by 37% and minimize recurrence problems by 28%.
Research Methodologies Used to Analyze the South Korea Antihistamine Market
The South Korea antihistamine market is analyzed through a combination of primary and secondary research methodologies to provide accurate market insights and future growth projections. Secondary research involves reviewing company annual reports, government healthcare policies, medical journals, pharmaceutical databases, and import-export statistics related to allergy treatment medications. Quantitative and qualitative analytical models are used to estimate market revenue, pricing trends, prescription volumes, and competitive positioning. The study highlights that second-generation antihistamines account for over 58% of market demand, while allergic rhinitis treatment applications contribute nearly 49% of antihistamine consumption across South Korea.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Antihistamine Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Antihistamine Market
- Pfizer Inc.
- UCB Pharma
- GSK plc
- Sanofi S.A.
- Bayer AG
- Chong Kun Dang Pharmaceutical Corp.
- Daewoong Pharmaceutical Co., Ltd.
- JW Pharmaceutical Corporation
- Hanmi Pharmaceutical Co., Ltd.
- Yuhan Corporation
Recent Developments:
- In March 2026, Geo Young reported cumulative sales exceeding 8 million units for Zyrtec between 2023 and 2025, maintaining over 60% market share within South Korea’s antihistamine segment.
- In November 2025, Chong Kun Dang Pharmaceutical accelerated investments in OTC allergy medication manufacturing and smart pharmaceutical production technologies supporting domestic antihistamine supply expansion.
Market Segmentation:
South Korea Antihistamine Market, By Drug Type
- First-Generation Antihistamines
- Second-Generation Antihistamines
- Combination Allergy Therapeutics
- Prescription Antihistamine Drugs
South Korea Antihistamine Market, By Technology
- AI-Based Pharmaceutical Research Platforms
- Smart Drug Delivery Systems
- Precision Allergy Therapeutics
- Digital Pharmacy Management Solutions
South Korea Antihistamine Market, By Application
- Allergic Rhinitis
- Urticaria & Skin Allergies
- Respiratory Allergies
- Food Allergies
- Drug Allergy Management
Expert Views:
The market for antihistamines in South Korea is set to record steady and sustainable growth fueled by high incidence rates of allergies, high demand for drugs that do not cause drowsiness, and investments made in advanced technology in the pharmaceutical industry. The introduction of AI drug discovery systems, advanced pharmaceutical systems, and advanced therapies for respiratory conditions is likely to boost efficiencies in treatment and increase demand for antihistamines in South Korea.
Author: Komal and Radhika By Spherical Insights and Consulting